Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | GBA1 | P04062 | 4/20 | 0.47 |
| ▸ | NCF1 | P14598 | 5/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | CYBB | P04839 | 1/20 | 0.39 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19775889 | 0.89 | CYP19A1 (0.50) | DRD2CYP19A1GBA1HRH4HRH3 | |
| SCHEMBL23267580 | 0.89 | GBA1 (0.48) | DRD2GBA1NCF1CYBBNOX5 | |
| SCHEMBL25920828 | 0.89 | GBA1 (0.48) | DRD2GBA1NCF1CYBBNOX5 | |
| SCHEMBL23267576 | 0.89 | GBA1 (0.48) | DRD2GBA1NCF1CYBBNOX5 | |
| SCHEMBL20631166 | 0.88 | DRD2 (0.55) | DRD2CYP19A1GBA1HRH4HRH3 | |
| SCHEMBL12033359 | 0.87 | GBA1 (0.49) | DRD2CYP19A1GBA1NCF1CYBB | |
| SCHEMBL19576157 | 0.86 | GBA1 (0.49) | DRD2GBA1NCF1CYBBNOX5 | |
| SCHEMBL19576173 | 0.86 | GBA1 (0.49) | DRD2GBA1NCF1CYBBNOX5 | |
| SCHEMBL19576084 | 0.86 | GBA1 (0.49) | DRD2GBA1NCF1CYBBNOX5 | |
| SCHEMBL20626139 | 0.85 | GBA1 (0.49) | DRD2CYP19A1GBA1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023288015-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |